Aldeyra The
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Aldeyra Therapeutics, Inc. Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) is a biotechnology company focused on discovering and developing innovative therapies that modulate reactive aldehyde species (RASP) to treat immune-mediated and metabolic diseases. The company offers a pipeline of investigational product candidates including reproxalap, a topical ocular RASP modulator in late-stage development via New Drug Application resubmission for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate formulation with U.S. FDA Orphan Drug Designation for primary vitreoretinal lymphoma, retinitis pigmentosa, and dry age-related macular degeneration/geographical atrophy; next-generation oral RASP modulators ADX-248 and ADX-246 for dermatologic, metabolic, retinal, and other immune-mediated conditions such as atopic dermatitis, obesity/hypertriglyceridemia, and CNS/neuroinflammatory diseases; and earlier-stage RASP modulators like ADX-629, which demonstrated statistically significant liver function improvements in Phase 2 trials for alcohol-associated hepatitis. Founded in 2004 and headquartered at 131 Hartwell Avenue, Suite 320, Lexington, Massachusetts, Aldeyra operates primarily in the United States with a focus on ophthalmology, dermatology, and systemic inflammatory disorders targeting patients underserved by existing single-target therapies. Recent developments include an expanded partnership with AbbVie in 2024-2025 providing up to $94 million upfront payment upon option exercise, $300 million in milestones including $100 million upon FDA approval of reproxalap, 60/40 U.S. profit-sharing in AbbVie's favor, tiered royalties ex-U.S., and 60% cost coverage for pre-commercial activities; a strategic pipeline refocus in October 2025 on next-generation RASP modulators ADX-248 and ADX-246 following positive ADX-629 data and culmination of its clinical proof-of-concept; resubmission of the reproxalap NDA addressing prior FDA Complete Response Letters with a PDUFA target date of December 16, 2025; and European Medicines Agency Orphan Designation for ADX-2191 in primary large B-cell lymphomas of immune-privileged sites including primary vitreoretinal lymphoma as of August 2025, extending cash runway into the second half of 2027.
Company News
Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Aldeyra Therapeutics to Host Regulatory Update Webcast
Levicept Appoints Darlene Deptula-Hicks as CFO
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
ALDX FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
ALDX UPCOMING DEADLINE : The Gross Law Firm Alerts Aldeyra Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
ALDX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
ALDX Deadline Tomorrow: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
ALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX